Immunome stock advances clinical pipeline after FDA clearance

Immunome (ISIN US45257U1088) closed at USD 21.17 on Nasdaq on October 6, 2026, while its market capitalization stood at USD 1.8 billion. The company is moving IM-1340 toward a Phase 1 study after a September 30 FDA clearance that expands its clinical oncology pipeline.

FDA clears the fifth program

According to Immunome on September 30, 2026, the U.S. Food and Drug Administration cleared the Investigational New Drug application for IM-1340, an antibody-drug conjugate aimed at advanced solid tumors.

The candidate uses Immunome's HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed across neuroendocrine tumors, lung cancer and colorectal cancer. The company expects to begin the open-label, multicenter Phase 1 study in the fourth quarter of 2026, making IM-1340 the fifth Immunome program in clinical development.

Quarterly loss keeps pressure on cash

Immunome's latest reported quarter ended June 30, 2026. MarketBeat reported adjusted EPS of USD -0.65 against consensus of USD -0.51, a USD 0.14 miss, while quarterly revenue was USD 0.00. Net loss reached USD 73.13 million in Q2/2026.

The balance sheet shows the funding challenge behind the development story. Cash and cash equivalents were USD 217.7 million at June 30, 2026, down from USD 653.5 million at December 31, 2025, while operating cash flow was negative USD 61.7 million in the quarter.

Consensus target remains higher

Analyst expectations remain divided around the clinical opportunity. MarketBeat listed a Moderate Buy consensus from 14 analysts and an average price target of USD 34.25, which lies 61.7 percent above the October 6 closing price of USD 21.17. The same overview cited Alliance Global Partners at Buy with a USD 32.00 target on September 21, 2026, and HC Wainwright at Buy with a USD 40.00 target on September 10, 2026.

The key near-term test is whether IM-1340 can translate preclinical activity into a clinical safety and efficacy signal. FDA clearance enables the trial, but the September 30 release also identifies clinical delays, unsuccessful development and non-predictive preclinical results as risks.

Immunome stock closes at USD 21.17

Immunome stock closed at USD 21.17 on Nasdaq on October 6, 2026. The 52-week range was USD 13.41 to USD 30.06, leaving the clinical pipeline and cash runway as the central valuation variables.

More news and analyses on Immunome stock